Journal of Cardiovascular Imaging

Korean Society of Echocardiography (한국심초음파학회)
권호 표지
DOI QR코드

DOI QR Code

TRANSIENT USE OF ORAL BOSENTAN CAN BE AN ADDITIONAL OPTION TO REDUCE PULMONARY ARTERIAL HYPERTENSION IN A PATIENT WITH SEVERE PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH ATRIAL SEPTAL DEFECT

  • Park, Yong-Kyu (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Park, Jae-Hyeong (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Yu, Jae-Hyeon (Department of Cardiovascular Surgery, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Kim, Jun-Hyung (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Lee, Jae-Hwan (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Choi, Si-Wan (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Jeong, Jin-Ok (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Seong, In-Whan (Cardiology Division of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital)
  • Published : 2011.09.27
⟨ Previous Next ⟩

Abstract

Atrial septal defect (ASD) with severe pulmonary arterial hypertension (PAH) is thought to preclude shunt closure. However, there are several reports that vasodilator treatment is associated with good clinical outcome in these patients, recently. We report a case of good clinical outcome in a patient with ASD and severe PAH successfully treated with operative closure of ASD and subsequent use of oral bosentan medication. This case supports that the corrective repair of ASD and an oral bosentan treatment can be one of the treatment options in the selected patients with severe PAH associated with ASD.

Keywords

References

  1. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:1037-42.
  2. Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon DC, Puga FJ, Kirklin JW, Danielson GK. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med 1990;323:1645-50.
  3. Kim YH, Yu JJ, Yun TJ, Lee Y, Kim YB, Choi HS, Jhang WK, Shin HJ, Park JJ, Seo DM, Ko JK, Park IS. Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy. Ann Thorac Surg 2010;89:1629-30.
  4. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7.
  5. Sachweh JS, Daebritz SH, Hermanns B, Fausten B, Jockenhoevel S, Handt S, Messmer BJ. Hypertensive pulmonary vascular disease in adults with secundum or sinus venosus atrial septal defect. Ann Thorac Surg 2006;81:207-13.
  6. Cherian G, Uthaman CB, Durairaj M, Sukumar IP, Krishnaswami S, Jairaj PS, John S, Krishnaswami H, Bhaktaviziam A. Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients. Am Heart J 1983;105:952-7.
  7. Craig RJ, Selzer A. Natural history and prognosis of atrial septal defect. Circulation 1968;37:805-15.
  8. Balint OH, Samman A, Haberer K, Tobe L, McLaughlin P, Siu SC, Horlick E, Granton J, Silversides CK. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart 2008;94:1189-93.
  9. Yamauchi H, Yamaki S, Fujii M, Iwaki H, Tanaka S. Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect. Ann Thorac Surg 2001;72:905-6; discussion 906-7.
  10. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
  11. Yamaki S, Horiuchi T, Miura M, Haneda K, Ishizawa E, Suzuki Y. Secundum atrial septal defect with severe pulmonary hypertension. Open lung biopsy diagnosis of operative indication. Chest 1987;91:33-8.